Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HEC68498 · 1 trial · 1 indication
Patients will receive study drug on a daily basis for 28 days according to the dose and schedule specified for a particular cohort of therapy. Toxicities observed in Cycle 0\&1 will be considered for dose limiting toxicity (DLT) and Maximum tolerated dose (MTD)determination
| Arm | Type | Description |
|---|---|---|
| HEC68498 | EXPERIMENTAL | HEC68498 will be administered daily |
| Name | Type | Description |
|---|---|---|
| HEC68498 | DRUG | HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib. |
Inclusion Criteria: （1）Target subjects 1. 18 years of age ≤ age ≤ 70 years of age, regardless of gender; 2. Patients with various types of advanced solid tumors confirmed by cytological or histological examination. Dose escalation test phase: including breast cancer, colorectal cancer, neuroen...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
HEC 68498 is an investigational small molecule being studied for Idiopathic Pulmonary Fibrosis and Advanced Refractory Solid Tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA.
HEC 68498 is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker SBFM.
HEC 68498 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials are ongoing to evaluate its safety and tolerability.
HEC 68498 has been studied in two completed Phase 1 trials. NCT03502902 evaluated safety, tolerability, and pharmacokinetics in healthy volunteers with Idiopathic Pulmonary Fibrosis. NCT04324372 studied the drug in patients with Advanced Refractory Solid Tumors.
Yes, HEC 68498 is the same drug as HEC68498. The name is sometimes written with or without a space, but it refers to the same investigational small molecule being developed by Sunshine Biopharma Inc.